M-current expressing neurons are neurons that express KCNQ2 and KCNQ3 potassium channel subunits, which collectively generate the M-current (I_M), a slowly activating and deactivating voltage-gated potassium current critical for neuronal excitability control. These neurons are widely distributed throughout the central and peripheral nervous systems and play essential roles in regulating action potential threshold, preventing repetitive firing, and modulating synaptic plasticity. KCNQ2/3 channels have emerged as important therapeutic targets for epilepsy, neuropathic pain, and potentially neurodegenerative diseases.
| Property | Value |
|----------|-------|
| Category | Ion Channel-Expressing Neurons |
| Location | Cortex, hippocampus, sympathetic ganglia, sensory neurons |
| Cell Types | KCNQ2/3-expressing neurons |
| Primary Neurotransmitter | Depends on neuron type |
| Key Markers | KCNQ2 (KV7.2), KCNQ3 (KV7.3), Kv7.2/7.3 immunoreactivity |
| Taxonomy |
ID |
Name / Label |
| Allen Brain Cell Atlas |
Search |
M-Current Expressing (KCNQ2/3) Neurons |
| Cell Ontology (CL) |
Search |
Check classification |
| Human Cell Atlas |
Search |
Check expression data |
| CellxGene Census |
Search |
Check cell census |
The M-channel is a heterotetrameric assembly:
- KCNQ2 (KV7.2): Encoded by KCNQ2 gene on chromosome 20
- KCNQ3 (KV7.3): Encoded by KCNQ3 gene on chromosome 8
- Stoichiometry: Typically 2 KCNQ2 + 2 KCNQ3 subunits
- Alternative subunits: KCNQ4, KCNQ5 in some tissues
The M-current exhibits unique characteristics:
- Activation: Slow (50-100 ms to half-maximal)
- Deactivation: Very slow (200-500 ms)
- Voltage dependence: Activates around -60 mV
- Single channel conductance: ~10 pS
- ** pharmacology**: Sensitive to retigabine, linopirdine
- Subunit composition: Required for functional channels
- Co-assembly: KCNQ2/KCNQ3 heteromers have optimal properties
- Trafficking: Proper membrane expression requires both subunits
- Ankyrin-G interaction: Anchoring at axon initial segment
KCNQ2/3 expressing neurons are found in:
- Cerebral cortex: Layer 2/3 and layer 5 pyramidal neurons
- Hippocampus: CA1 pyramidal cells, dentate gyrus granule cells
- Thalamus: Relay neurons, interneurons
- Basal ganglia: Striatal medium spiny neurons
- Cerebellum: Purkinje cells, granule cells
- Brainstem: Motor nuclei, sensory relay neurons
- Sympathetic ganglia: Postganglionic neurons
- Sensory neurons: Dorsal root ganglion (DRG) nociceptors
- Autonomic nervous system: Enteric neurons
The M-current regulates neuronal properties:
- Membrane potential: Stabilizes resting membrane potential
- Spike threshold: Raises action potential threshold
- Firing pattern: Prevents repetitive firing, promotes accommodation
- Afterhyperpolarization: Modulates afterhyperpolarization
KCNQ2/3 channels influence learning and memory:
- Dendritic integration: Back-propagating action potentials
- LTPmechanisms/long-term-potentiation) induction: Hippocampal long-term potentiation
- Learning paradigms: Spatial and contextual memory
- Homeostatic plasticity: Synaptic scaling
In sensory neurons:
- Nociceptor excitability: Reduces pain signaling
- Peripheral sensitization: Prevents hyperexcitability
- Neuropathic pain: Loss of M-current contributes to chronic pain
- Sympathetic tone: Regulates sympathetic output
- Heart rate: Cardiac parasympathetic modulation
- Gastrointestinal: Enteric nervous system function
KCNQ2/3 channels may influence AD pathogenesis:
- Neuronal hyperexcitability: Early feature of AD
- Amyloid effects: Aβ reduces M-current function
- Tau pathology: Hyperphosphorylation affects channel trafficking
- Calcium dysregulation: M-channel failure increases Ca²⁺ influx
- Network oscillations: Dysregulated gamma oscillations
In PD:
- Subthalamic nucleus: M-current deficits in STN neurons
- Motor cortex hyperexcitability: Contributes to parkinsonism
- Levodopa-induced dyskinesias: Altered M-channel expression
- Neuroprotection potential: KCNQ2/3 agonists may protect neurons
KCNQ2/3 mutations cause epilepsy:
- Benign neonatal seizures: KCNQ2/3 mutation phenotypes
- Early infantile epileptic encephalopathy: Severe mutations
- Temporal lobe epilepsy: Altered M-channel expression
- Anti-epileptic drugs: Retigabine as KCNQ2/3 opener
KCNQ2/3 in chronic pain:
- Sensitization: Nerve injury reduces M-current
- Inflammatory pain: Cytokine effects on channels
- Chemotherapy-induced neuropathy: Taxol, vincristine effects
- Therapeutic target: KCNQ2/3 openers for pain relief
- Motor neuron vulnerability: M-channel dysfunction
- Excitotoxicity: Reduced M-current increases glutamate sensitivity
- Therapeutic potential: Channel modulators
- Benign familial neonatal seizures (BFNS1): Loss-of-function mutations
- Early infantile epileptic encephalopathy 7 (EIEE7): Severe de novo mutations
- Mosaic mutations: Can cause focal seizures
- Benign familial neonatal seizures (BFNS2): Less common than KCNQ2
- Epilepsy-ataxia syndrome: Channel dysfunction
- Retigabine (Azilect): FDA-approved for epilepsy
- Flupirtine: Analgesic properties
- BMS-204352: Experimental compound
- Pyrazole derivatives: Newer compounds
- Epilepsy: Reduces seizure frequency
- Neuropathic pain: Analgesic effects
- Stroke: Potential neuroprotection
- Migraine: Cortical spreading depression prevention
- Sedation: CNS depression
- Dizziness: Vestibular effects
- Weight gain: Metabolic effects
- Blurred vision: Retinal effects
- Patch-clamp recording: Current-voltage relationships
- Single-channel analysis: Channel kinetics
- Voltage-clamp: Current isolation
- Current-clamp: Firing pattern analysis
- Western blot: Protein expression
- Immunohistochemistry: Localization
- CRISPR/Cas9: Genetic manipulation
- siRNA: Knockdown studies
- Knockout mice: Kcnq2-/-, Kcnq3-/-
- Transgenic lines: Conditional knockouts
- Epilepsy models: Kcnq2 mutant mice
- Pain models: Nerve injury paradigms